MPMahendar Porika

Mahendar Porika

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Mahendar Porika has a total of 10 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Nanotoxicology meets smart polymers: advancing safety-by-design nanomaterials

    by Gaurav Tiwari, Ruchi Tiwari, Anand Badrivishal Mundada, Pooja Anand Mundada, Rakhee Maheshwari, Shashi Ravi Suman Rudrangi, Mahendar Porika, Radhika Tippani, Pankaj Sharma

    Smart polymers have played great role in enhancing nanomedical application areas in drug delivery, diagnosis and environment sensitive treatment systems. Nonetheless, their highly adaptive and structurally diverse nature leads to more concern toward their methods of action and their safety in the nanoscale. Thus, this review seeks to provide an informed account of how smart polymers can act as vectors of biomedical advancement as well as drivers of biological interactions that have not had a favorable outcome. Using a PRISMA 2020-informed reporting principle, this work presents a narrative and critical synthesis of in vitro and in vivo investigating the nanotoxicology of smart polymer-based nanosystems. Accordingly, no formal meta-analysis was undertaken. Oxidative stress, immune response, and organ injury are observed as the critical issues, whereas the factors, including the surface modification of nanoparticles and biodegradation, are the significant predictors of safer nanoparticles. In addition, it highlights high-throughput screening, artificial intelligence based modeling and quantitative or physiologically based simulations as some of the promising approaches to predictive toxicology to support safe-by-design strategies. These findings show that there is a need for polymer type regulation and ethical measures to promote safe use of smart polymers in future health care sectors.


  • Open Access

    CRISPR/Cas: A New Tool in the Research of Telomeres and Telomerase as Well as a Novel Form of Cancer Therapy

    by Mahendar Porika, Radhika Tippani, Gabriele Christine Saretzki

    Due to their close connection with senescence, aging, and disease, telomeres and telomerase provide a unique and vital research route for boosting longevity and health span. Despite significant advances during the last three decades, earlier studies into these two biological players were impeded by the difficulty of achieving real-time changes inside living cells. As a result of the clustered regularly interspaced short palindromic repeats (CRISPR)-associated system’s (Cas) method, targeted genetic studies are now underway to change telomerase, the genes that govern it as well as telomeres. This review will discuss studies that have utilized CRISPR-related technologies to target and modify genes relevant to telomeres and telomerase as well as to develop targeted anti-cancer therapies. These studies greatly improve our knowledge and understanding of cellular and molecular mechanisms that underlie cancer development and aging.